In intensive care medicine, various plasma proteins from Biotest are already in use today, for instance as volume and protein replacement in severe injuries and burns and also for the treatment of severe bacterial infections (e.g. sepsis).
Continuing this practice, Biotest is developing the IgM and IgA-enriched polyvalent antibody preparation trimodulin for the treatment of severe community acquired pneumonia. The similarity of symptoms in severe COVID-19 to symptoms of sCAP patients suggests a considerable potential for trimodulin also in the treatment of SARS-CoV-2 induced pneumonia.
Moreover, we are developing an innovative fibrinogen concentrate, used amongst others to treat life-threatening bleedings.
